Effect of empagliflozin on ketone bodies in patients with stable chronic heart failure

por Pietschner, R., Kolwelter, J., Bosch, A., Striepe, K., Jung, S., Kannenkeril, D., Ott, C., Schiffer, M., Achenbach, S., Schmieder, R. E.
Publicado 2021

SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial

por Karg, M. V., Bosch, A., Kannenkeril, D., Striepe, K., Ott, C., Schneider, M. P., Boemke-Zelch, F., Linz, P., Nagel, A. M., Titze, J., Uder, M., Schmieder, R. E.
Publicado 2018

NT-proBNP and stem cell factor plasma concentrations are independently associated with cardiovascular outcomes in end-stage renal disease hemodialysis patients

por Rossignol, P, Duarte, K, Bresso, E, A, Åsberg, Devignes, M D, Eriksson, N, Girerd, N, Glerup, R, Jardine, A G, Holdaas, H, Lamiral, Z, Leroy, C, Massy, Z, März, W, Krämer, B, Wu, P H, Schmieder, R, Soveri, I, Christensen, J H, Svensson, M, Zannad, F, Fellström, B
Publicado 2022